Publication:
Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.

Simple item page
dc.contributor.authorArgüelles Arias, Federico
dc.contributor.authorHinojosa Del Val, Joaquín
dc.contributor.authorVera Mendoza, Isabel
dc.date.accessioned2023-01-25T10:04:57Z
dc.date.available2023-01-25T10:04:57Z
dc.date.issued2018
dc.description.abstractIn 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing spondylitis. The same year, our Society published a position statement that was later reviewed.
dc.identifier.doi10.17235/reed.2018.5456/2018
dc.identifier.issn1130-0108
dc.identifier.pmid29527903
dc.identifier.unpaywallURLhttps://doi.org/10.17235/reed.2018.5456/2018
dc.identifier.urihttp://hdl.handle.net/10668/12230
dc.issue.number6
dc.journal.titleRevista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
dc.journal.titleabbreviationRev Esp Enferm Dig
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.page.number407
dc.pubmedtypeLetter
dc.rights.accessRightsopen access
dc.subject.meshAnti-Inflammatory Agents
dc.subject.meshBiosimilar Pharmaceuticals
dc.subject.meshHumans
dc.subject.meshInflammatory Bowel Diseases
dc.subject.meshInfliximab
dc.subject.meshPractice Guidelines as Topic
dc.titleUpdate of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number110
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía